While resmetirom was specifically designed to target the liver to correct the dysfunctional THR-β signaling in patients with NASH, it is critical to ensure that resmetirom does not affect the more widely expressed THR-α receptor, which is responsible for thyroid hormone activity in the heart and bone. Here, TG is linked to metabolic dysfunction-associated steatohepatitis.